louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04734925: Study of the Impact of an Intervention Performed by a Clinical Pharmacist on Patients At Risk of Pneumococcal Infection At the End of Hospitalization
Official title: Study of the Impact of an Intervention Performed by a Clinical Pharmacist on Patients At Risk of Pneumococcal Infection At the End of Hospitalization
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vaccination
Keywords: antipneumococcal
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2021-02-02
Enrollment: 167
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients hospitalized in the Vascular Surgery and Pneumology Departments of Nimes University Hospital

Brief summary: In France, Streptococcus pneumoniae is the leading agent involved in community-acquired bacterial pneumopathies and bacterial meningitis. The frequency of these infections is increasing in at-risk subjects. Paradoxically, pneumococcal vaccination coverage in this type of patient is limited at the national level, even though the French High Council for Public Health (HCSP) has been extending the 13-valent conjugate and 23-valent non-conjugate double vaccination in this target population since March 2017.

These patients generally benefit from regular medical follow-up involving several health professionals in hospital or outpatient clinics. In spite of this, one of the factors identified as a hindrance to pneumococcal vaccination is the absence of a proposal from the doctor.

We would like to assess compliance with the recommendations for pneumococcal vaccination according to the High Council of Public Health (HCSP) in at-risk patients leaving hospital. We also wish to measure the potential impact of an intervention by the clinical pharmacist on the application of these recommendations.


Eligibility criteria: Inclusion Criteria:

* Hospitalization in one of the departments participating in the study
* At risk of pneumococcal infection according to HCSP recommendations (1)
* Negative pneumococcal vaccination status
* Adult patient (≥18 years old)

Exclusion Criteria:

* Under safeguard of justice
* Unable to receive informed information
* Patient having objected to the use of their data.

Primary outcomes:
measure: vaccine protocols dispensed by dispensing pharmacists.
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Nîmes
country: France
facility: Chu Nimes
Study officials:
References:
Clinical trial NCT04360525: Different Clinicopathological Features of Non-Elderly Sigmoid Volvulus Patients
Official title: Different Clinicopathological Features of Non-Elderly Sigmoid Volvulus Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pathology
Keywords: dolichocolon
volvulus
sigmoid
Parkinson
mental retardation
Hirschsprung's disease
Lead sponsor: Dr. Ersin Arslan Education and Training Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Inonu University
First posted: 2020-04-24
Enrollment: 134
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who were treated for the sigmoid volvulus between 2009 and 2018 at Inonu University General Surgery Clinic.

Brief summary: Sigmoid volvulus is frequently seen in male patients over 60 years old. In the sigmoid volvulus \<60 age groups, the male/female ratio is close to each other. If sigmoid volvulus develops in \<60 age groups, it is more likely to be another underlying organic pathology.

Detailed description: Sigmoid volvulus is frequently seen in male patients over 60 years old. Here, the investigators aimed to investigate the causes of sigmoid volvulus developing in patients under 60 years of age. Patients diagnosed with sigmoid volvulus between 2009 and 2018 were retrospectively screened. The patients were divided into two as under 60 years old and above. The co-morbidity, mortality, morbidity, complications, age and gender data of the patients were analyzed. In the sigmoid volvulus \<60 age groups, the male/female ratio is close to each other. If sigmoid volvulus develops in \<60 age groups, it is more likely to be another underlying organic pathology.

Eligibility criteria: Inclusion Criteria:

* Sigmoid volvulus patients under the age of 60
* Sigmoid volvulus patients at the age of ≥60

Exclusion Criteria:

* Lack of data

Primary outcomes:
measure: Mortality
timeFrame: up to three months
measure: Morbidity
timeFrame: up to three months
Secondary outcomes:
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: Dr. Ersin Arslan Training and Resource Hospital
Study officials:
affiliation: Dr. Ersin Arslan Training and Resource Hospital
name: ufuk uylas, Specialist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05508425: Comparing the Effects of Water Temperature and Actives in Glucose Solution on Pregnant Women
Official title: Comparing the Effects of Water Temperature and Actives in Glucose Solution on Pregnant Women's Taste and Side Effects During an Oral Glucose Tolerance Test-A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gestational Diabetes Mellitus
Lead sponsor: Chiayi Christian Hospital
Sponsor class: OTHER
First posted: 2022-08-19
Enrollment: 400
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: To assess the effect of water temperature and additives on pregnant women's taste and side effect during the oral glucose tolerance test (OGTT) evaluation.


Eligibility criteria: Inclusion Criteria:

* Pregnant women
* Gestational age between 24 and 28 weeks

Exclusion Criteria:

* Clinical diagnosis of overt type 2 diabetes
* Clinical diagnosis of facial palsy
* Clinical diagnosis of oral cavity and throat
* Clinical diagnosis of hypothyroidism
* Clinical diagnosis of chronic hepatitis
* Clinical diagnosis of kidney disease .Clinical diagnosis of Sicca syndrome.

Primary outcomes:
measure: Glycaemia level
timeFrame: Glycaemia level was measured just before glucose administration.
measure: Glycaemia level
timeFrame: Glycaemia level was measured at 1 hour after glucose administration
measure: Glycaemia level
timeFrame: Glycaemia level was measured at 2 hours after glucose administration
measure: gestational diabetes mellitus
timeFrame: Just before glucose administration.
measure: gestational diabetes mellitus
timeFrame: At 1 hour after glucose administration
measure: gestational diabetes mellitus
timeFrame: At 2 hour after glucose administration
measure: Satisfaction after glucose solution administration
timeFrame: Just after glucose administration
measure: Taste after glucose solution administration
timeFrame: Just after glucose administration
measure: Nausea after glucose solution administration
timeFrame: Just after glucose administration
measure: Vomiting after glucose solution administration
timeFrame: Just after glucose solution administration
measure: Headache after glucose solution administration
timeFrame: Just after glucose solution administration
measure: Abdominal bloating after glucose solution administration
timeFrame: Just after glucose solution administration
Secondary outcomes:
Other outcomes:
Locations:
city: Chiayi City
country: Taiwan
facility: Ditmanson Medical Foundation Chia-Yi Christian Hospital
Study officials:
References:
Clinical trial NCT03124225: Ultrasound Utility in Routine Clinical Practise
Official title: The Impact of Rheumatologist-performed Ultrasound on Diagnosis and Management of Inflammatory Arthritis in Routine Clinical Practice
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Arthritis, Rheumatoid
Ultrasonography
Lead sponsor: Barts & The London NHS Trust
Sponsor class: OTHER
First posted: 2017-04-21
Enrollment: 258
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Early Arthritis patients

Brief summary: The aim of this research study is to describe the impact of rheumatologist performed ultrasound on the diagnosis and management pathways of patients with rheumatoid arthritis. Primarily, to compare the time from first visit to treatment initiation between patients with and without rheumatologist-performed ultrasound assessment.

Detailed description: There are currently no guidelines for best practice in the use of ultrasound in RA and interim results from a survey by the British Society of Rheumatology (BSR) in this area have suggested that practice is variable across the UK. NICE recognize that the earlier persistent synovitis is identified and treated with disease modifying anti-rheumatic drugs DMARDs, the better the long term outcome and have welcomed the need to determine the role of imaging in assisting with this early diagnosis, and whether the added cost is justified by better disease outcomes.

This is a multi-site prospective observational study which investigates the use of ultrasound imaging in the context of patients with early arthritis presenting to secondary care. The time to commencement of DMARD therapy and diagnosis of Rheumatoid arthritis are therein outcome measures. Patients are followed up for 12 months after their first presentation and time to diagnosis or DMARD commencement recorded.

Eligibility criteria: Inclusion Criteria:

* Patients aged ≥18 years at the time of presentation to the clinic Patients newly presenting to the rheumatology clinic with suspected inflammatory arthritis

Exclusion Criteria:

* For the non-ultrasound arm; patients who have been referred to another rheumatologist or radiologist for ultrasound Patients who decline or who are unable to consent to the use of their medical records for research

Primary outcomes:
measure: To compare the time from first visit to treatment initiation between patients with and without rheumatologist-performed ultrasound assessment
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00875225: Using Multimedia Technology for Hypertension Control for Low-Income African Americans
Official title: Culturally Sensitive Intervention: CSI Birmingham
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypertension
Keywords: Hypertension
Adherence to medications
Lead sponsor: Cooper Green Mercy Hospital
Sponsor class: OTHER
Collaborators: name: University of Alabama at Birmingham
First posted: 2009-04-03
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to test an interactive DVD intervention to encourage patients to stick to their blood pressure medication in order to achieve blood pressure control for African American patients. The intervention will convey health messages through personal patient stories who have dealt with or continue to struggle with high blood pressure.

Hypothesis 1: At the end of 9 months a higher proportion of patients randomized to the intervention group will achieve appropriate blood pressure control.

Hypothesis 2: At the end of 9 months a higher proportion of patients who randomized to the intervention group will report high adherence to their hypertension medications.


Eligibility criteria: Inclusion Criteria:

* African American
* Clinical Diagnosis of Hypertension
* Patient at Cooper Green Hospital
* Provided Informed Consent
* Age 18 or older

Exclusion Criteria:

* Pregnant
* Diagnosed with dementia, schizophrenia, bipolar illness, or other serious acute or chronic medical co-morbidity

Primary outcomes:
measure: Blood pressure control
timeFrame: Two years
Secondary outcomes:
measure: Adherence to hypertension medications
timeFrame: Two years
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Cooper Green Mercy Hospital
state: Alabama
Study officials:
affiliation: Cooper Green Mercy Hospital
name: Sandral Hullett, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Houston TK, Allison JJ, Sussman M, Horn W, Holt CL, Trobaugh J, Salas M, Pisu M, Cuffee YL, Larkin D, Person SD, Barton B, Kiefe CI, Hullett S. Culturally appropriate storytelling to improve blood pressure: a randomized trial. Ann Intern Med. 2011 Jan 18;154(2):77-84. doi: 10.7326/0003-4819-154-2-201101180-00004.
Clinical trial NCT03960125: Photodynamic Therapy and Microvesicles
Official title: Photodynamic Therapy and Microvesicles
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: EARLY_PHASE1
Conditions: Photodynamic Therapy
Microvesicle Particle
Lead sponsor: Wright State University
Sponsor class: OTHER
First posted: 2019-05-22
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study is designed to test whether localized photodynamic therapy (PDT) treatment will result in increased skin levels of microvesicle particle (MVP) and if the use of imipramine will counteract PDT generated MVP release. The effects of PDT and ultraviolet B radiation (UVB) on platelet-activating factor (PAF) and MVP production have long been part of the PI's research experience. To test this, the investigator plans to enroll up to enroll up to 12 male subjects whom are aged 21 to age 45. These subjects will be treated with topical 5-aminolevulinic acid gel (Ameluz) to small areas of forearm followed by treatment with blue light. The areas will then be treated with either 4% imipramine cream or cream base as control. Four hours later, the redness of the areas will be measured using a mexameter and MVPs measured in skin biopsies taken from PDT-treated skin.


Eligibility criteria: Inclusion Criteria:

* Male adult subjects age 21 to age 45
* Skin type must be "fair", Fitzpatrick type I or II
* Able to understand/complete informed/consent
* Have access to stable transportation

Exclusion Criteria:

* Underlying diseases that could affect wound healing (e.g., diabetes mellitus)
* Taking medications that are known photosensitizers (e.g., doxycycline) or anti- inflammatories (e.g., NSAIDS \[except for low-dose aspirin\] or steroids)
* Have a history of abnormal scarring (e.g., keloids)
* Taking vitamin C or E supplements for past month
* Utilizing imipramine or any other tricyclic antidepressant (oral or cream)
* Utilizing topical anti-inflammatory or systemic agents (eg, prednisone)
* Tanning bed use within last 3 months
* PDT or UVB treatments in past 3 months

Primary outcomes:
measure: Change in Microvesicle Particle Levels From Baseline with Photodynamic Therapy.
timeFrame: Day 0
measure: Change in Microvesicle Particle Levels From Baseline with 4% Imipramine Cream Treatment.
timeFrame: Day 2
Secondary outcomes:
measure: Change in Erythema From Baseline Due to Photodynamic Therapy
timeFrame: Day 2
measure: Change in Skin Pain From Baseline Due to Photodynamic Therapy
timeFrame: Day 2
measure: Change in Itch From Baseline Due to Photodynamic Therapy
timeFrame: Day 2
Other outcomes:
Locations:
city: Fairborn
country: United States
facility: Wright State Physicians
state: Ohio
Study officials:
affiliation: Wright State Physicians
name: Jeffrey B Travers, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04312425: Classic and Modified Rapid Sequence Induction for Prevention of Gastric Content Regurgitation
Official title: Comparison of Classic and Modified Rapid Sequence Induction on Prevention of Perioperative Gastric Content Regurgitation in Emergency Surgery Under General Anesthesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rapid Sequence Induction
Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
Sponsor class: OTHER
First posted: 2020-03-18
Enrollment: 8601
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients receive emergency surgery under general anesthesia.

Brief summary: Induction of anesthesia induces a loss of protective upper airway reflexes and is associated with gastric content regurgitation. Emergency surgery bears a higher risk of gastric content regurgitation because of full stomach, delayed gastric emptying, intestinal obstruction, stroke or other factors. Rapid sequence induction (RSI) of anesthesia was recommended to minimize the risk of regurgitation and aspiration. Classic RSI scheme mainly includes the use of short-acting sedatives and muscle relaxant, together with a manual pressure to the cricoid cartilage (Sellick maneuver) which aims at compressing the esophagus to avoid regurgitation. Though widely recommended, the scheme has been controversial for years. Our department modified the scheme and put it into use in day shift emergency surgery since March 1, 2018. This retrospective analysis is aimed at comparing the effect of classic and modified rapid sequence induction in prevention of gastric content regurgitation in emergency surgery under general anesthesia.


Eligibility criteria: Inclusion Criteria:

* Patients receive emergency surgery under general anesthesia March 1, 2015 to February 29, 2020
* Eighteen years or older

Exclusion Criteria:

* Trachea intubation status on admission
* Tracheotomy
* Bronchoscope surgery
* General anesthesia with laryngeal mask
* Awake intubation

Primary outcomes:
measure: Incidence of gastric content regurgitation
timeFrame: From entering operation room to endotracheal intubation completed.
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The First Affiliated Hospital of Nanjing Medical University
state: Jiangsu
Study officials:
affiliation: The First Affiliated Hospital with Nanjing Medical University
name: Zhengnian Ding, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07026825: Surgical Resection Enhances Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Study
Official title: Surgical Resection Improves Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Propensity-Matched Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastric-type Endocervical Adenocarcinoma
Lead sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Sponsor class: OTHER
First posted: 2025-06-18
Enrollment: 308
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study enrolled patients aged 18 years and older with histologically confirmed gastric-type endocervical adenocarcinoma and no prior history of other malignancies.

Brief summary: This retrospective cohort study analyzes the effect of surgical resection on survival outcomes in patients with gastric-type endocervical adenocarcinoma (GAS), using data from the SEER database (2000-2021). Propensity score matching and multivariable Cox regression were used to compare overall survival (OS) and tumor-specific survival (TSS) between patients who underwent surgery and those who did not. The study aims to determine whether primary tumor resection is associated with improved survival across tumor sizes and stages.

Detailed description: The study utilized de-identified data from the SEER program encompassing women aged ≥18 with histologically confirmed gastric-type endocervical adenocarcinoma between 2000 and 2021. The primary endpoints were overall survival and tumor-specific survival. Statistical analyses included multivariable Cox regression, propensity score matching (2:1), and inverse probability of treatment weighting (IPTW). Subgroup analyses were performed based on FIGO stage and tumor size (\>4 cm). A total of 308 eligible cases were included. No patient interaction or clinical intervention occurred.

Eligibility criteria: Inclusion Criteria:

Histologically confirmed gastric-type endocervical adenocarcinoma Cervix as the first primary site Diagnosis between 2000 and 2021

Exclusion Criteria:

Incomplete survival or treatment data Diagnosis not confirmed microscopically

Primary outcomes:
measure: Outcome
timeFrame: Time from diagnosis to death from any cause Up to 22 years (2000-2022)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04766125: Psychological Factors in Cardiac Surgery
Official title: Psychological Factors in Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Conditions
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
First posted: 2021-02-23
Enrollment: 103
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The study investigates the effect of adverse event information on adverse event occurrence in patients undergoing elective cardiac surgery in a two-armed, randomized study. One group will receive standard information about adverse events; the second group will receive a standardised elaboration of the standard information. Hypothesis: Elaborated information about adverse events will increase adverse event occurrence, mediated by expectations and anxiety, and moderated by coping style.

Detailed description: If quality assessment indicates that the protocol was not followed adequately, participants will be excluded from data analysis.

Eligibility criteria: Inclusion Criteria:

* Adults (18 and older) undergoing elective cardiac surgery at the Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital

Exclusion Criteria:

* Patients who have previously had cardiac surgery
* Cardiac surgery with deep hypothermia (\<32 degrees Celsius)
* Acute surgery
* Patients with psychiatric or neurological disease who are unable to collaborate with the study protocol
* Patients who do not speak/read Danish

Primary outcomes:
measure: Number of adverse events
timeFrame: Assessed on day four
Secondary outcomes:
measure: Number of adverse events
timeFrame: Assessed on day 30, 90, and 180
measure: Intensity of experienced adverse events
timeFrame: Assessed on day four, 30, 90, and 180
measure: Hospital readmission
timeFrame: Assessed on day 180
measure: Occurrence of specific adverse events
timeFrame: Assessed on day four, 30, 90, and 180
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University
Study officials:
affiliation: University of Aarhus
name: Mette Sieg
role: PRINCIPAL_INVESTIGATOR
References: